The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

About this episode

The episode features a discussion on the challenges of drug discovery in relation to chronic liver disease, highlighting the roles of AI and transcriptomics.

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI da...

People in this episode

Guests: Quin Wills, Stéphane Barges

Topics covered

• drug discovery
• AI in biotech
• RNA therapies
• transcriptomics
• chronic liver disease

Keywords

• drug discovery
• AI
• RNA therapies
• transcriptomics
• chronic liver disease

Mentioned in this episode

Organizations: Ochre Bio, Lexogen

More episodes of Beyond Biotech - the podcast from Labiotech

• Advancing corticosteroids and hormonal therapies for supply and scale · June 12, 2026 · 27 min
• Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media · June 5, 2026 · 44 min
• World MS Day Special: Immunic reveals new hope for progressive MS · May 29, 2026 · 28 min
• Freeze variability, not progress: strengthen your cell therapy supply chain from the start · May 15, 2026 · 30 min
• Making labs smarter for scientific breakthroughs · May 7, 2026 · 31 min
• How Epicrispr is leveraging CRISPR without cutting DNA · April 30, 2026 · 33 min